KR102294445B1 - Infant and child origin lactic acid bacteria Lactobacillus paracasei MG4592 and composition comprising the lactic acid bacteria for enhancing intestine activity, anti-oxidant and anti-obesity - Google Patents

Abstract

The present invention relates to a strain of Lactobacillus paracasei MG4592 isolated from the feces of infants or toddlers, and a use of preventing, alleviating and treating obesity or obesity-related diseases thereof. According to the present invention, since the Lactobacillus strain is isolated from the human body, more specifically, from the feces of selective infants, it is safe, exhibits properties suitable for probiotics, and has excellent inhibition activity of lipid accumulation, inhibition activity of alpha-glucosidase and anti-oxidant capacity. Therefore, the Lactobacillus strain can be widely used in various fields for the prevention, alleviation and treatment of obesity or obesity-related diseases.

Description

Infant and child origin lactic acid bacteria Lactobacillus paracasei MG4592 and composition comprising the lactic acid bacteria for enhancing intestine activity, anti-oxidant and anti-obesity composition comprising the same anti-obesity}

The present invention relates to a Lactobacillus paracasei MG4592 strain isolated from the feces of infants or infants and its use for preventing, improving and treating obesity or obesity-related diseases.

Lactobacillus has a special physiological activity ability, and is generally treated as a safe strain (GRAS, generally regarded as safe bacteria). Lactobacillus is not only used in the production of various fermented foods, but is also widely used in dairy and fermented vegetable products with functional and probiotic properties. Recently, as consumer demand for natural supplements that replace chemical supplements increases, it is emerging as an alternative solution. Probiotics are living microorganisms that have a very beneficial effect on the health of the host animal, improving the balance of the intestinal microflora and enhancing the absorption of nutrients. In addition, probiotics have the characteristic of showing the antibacterial action of pathogenic microorganisms in the intestinal environment. Probiotics include various microorganisms, but the genera Lactobacillus and Bifidobacterium occupy the largest distribution. In particular, the genus Lactobacillus is generally used in the fermentation process of dairy products, meat, fruits and vegetables and cereal products.

Obesity is known as a major cause of heart disease, cancer, arthritis, and diabetes, and despite the increasing public awareness for solving obesity, obese patients are continuously increasing. Obesity appears as the number of adipocytes increases as a result of adipogenesis and the lipid content of adipocytes increases. Adipocytes play a major role in synthesizing and storing excess calories as triglycerides, and as a result of adipogenesis, the size and number of adipocytes increases and intracellular lipid accumulation is accelerated. In addition, obesity causes lipotoxicity and oxidative stress, and insulin resistance, which can lead to hyperglycemia, which is the cause of various obesity-related diseases.

However, conventional therapeutic agents for treating obesity and obesity-related diseases have side effects such as heart disease, respiratory disease, and nervous system disease and also have low continuity of efficacy, so it is necessary to develop a more improved anti-obesity drug, and There are few products that have satisfactory therapeutic effects without side effects, so the development of new anti-obesity drugs is required.

delete

US 10-2017-0119099 A US 10-2009-0113478 A US 10-2015-0098202 A

Ameliorative Effects of Probiotic Lactobacillus paracasei NL41 on Insulin Sensitivity, Oxidative Stress, and Beta-Cell Function in a Type 2 Diabetes Mellitus Rat Model (Mol. Nutr. Food Res. 2019, 63, 1900457) Probiotics L. Plantarum and L. Curvatus In Combination Alter Hepatic Lipid Metabolism and Suppress Diet-Induced Obesity (Obesity (2013) 21, 2571-2578. doi:10.1002/oby.20428)

The present inventors conducted research to obtain probiotics with enhanced anti-obesity, anti-diabetic and antioxidant functions that can be applied to food and pharmaceutical supplements. It was confirmed that it can be effectively used in obesity-related diseases, and the present invention was completed.

Accordingly, an object of the present invention is to provide a lactic acid bacterium having an effect of preventing, treating, and improving obesity or obesity-related diseases.

In order to achieve the above object, the present invention provides a Lactobacillus paracasei MG4592 strain (Accession No.: KCTC 14435BP).

In addition, the present invention provides a food composition for preventing or improving obesity or obesity-related diseases, comprising the strain, its culture medium, or a cell-free extract thereof.

In addition, the present invention provides a health functional food composition for preventing or improving obesity or obesity-related diseases, comprising the strain, its culture medium, or a cell-free extract thereof.

In addition, the present invention provides a pharmaceutical composition for preventing or treating obesity or obesity-related diseases, comprising the strain, its culture medium or a cell-free extract thereof.

In addition, the present invention provides a quasi-drug composition for preventing or improving obesity or obesity-related diseases comprising the strain, its culture medium, or a cell-free extract thereof.

In addition, the present invention provides a feed composition for preventing or improving obesity or obesity-related diseases comprising the strain, its culture medium, or a cell-free extract thereof.

The lactic acid strain isolated from the feces of infants and young children selected in the present invention is not only safe as it is separated from the human body, but also exhibits properties suitable for probiotics, and has excellent lipid accumulation inhibitory ability, α-glucosidase inhibitory ability and antioxidant activity, and obesity or obesity-related It can be widely used in various fields for the prevention, improvement and treatment of diseases.

1 is a diagram showing the results of examining the effects of the selected seven strains on α-glucosidase activity.
2 is a diagram showing the results of confirming the antioxidant capacity of each strain measured through DPPH free radical scavenging activity and ABTS free radical scavenging activity.
3 is a diagram showing electron micrographs of each strain, Lactobacillus acidophilus MG4558 (A), Lactobacillus paracasei MG4592 (B), Lactobacillus plantarum MG4553 (C), Lactobacillus plantarum MG4555 (D), Lactobacillus rhamnosus MG4502 (E), Lactobacillus rhamnosus MG4505 (F), and Lactobacillus rhamnosus MG4511 (G). All strains were 10,000x magnification, Lactobacillus rhamnosus MG4505 5,000x magnification.

The present invention is Lactobacillus acidophilus MG4558 (Accession No. KCTC14438BP), Lactobacillus paracasei MG4592 (Accession No.: KCTC 14435BP), Lactobacillus plantarum MG4553 (Accession No.: KCTC14097BP), Lactobacillus plantarum (Accession No.: KCTC14097BP), Lactobacillus plantarum ( Accession No.: KCTC 14437BP) or Lactobacillus rhamnosus MG4502 (Accession No.: KCTC 14095BP).

All of the above strains of the present invention are strains isolated from the feces of infants or infants, and are human-derived lactic acid strains, which are characterized as safe strains when ingested in the body. characterized.

Hereinafter, the present invention will be described in detail.

Lactobacillus acidophilus MG4558 (Accession No. KCTC14438BP), Lactobacillus paracasei MG4592 (Accession No.: KCTC 14435BP), Lactobacillus plantarum MG4553 (Accession No.: KCTC14097BP), Lactobacillus plantarum of the present invention Accession No.: KCTC 14437BP) or Lactobacillus rhamnosus MG4502 (Accession No.: KCTC 14095BP) strain is a novel strain capable of preventing, treating or improving obesity or obesity-related diseases. As used herein, the term "Lactobacillus" is a bacterium that produces a large amount of lactic acid by fermenting saccharides widely distributed in nature to obtain energy.

In the present invention, feces are collected from infants and toddlers, preferably from 2 to 15 months of age, filtered and diluted to obtain strains present in feces, and strains exhibiting excellent activity are selected from them.

The selected strain was identified as Lactobacillus based on the results of 16S rRNA gene sequencing, and was given the following accession number: Lactobacillus acidophilus MG4558 (Accession No. KCTC 14438BP, accession date 2021.01.06), Lactobacillus Paracase J MG4592 (Accession No.: KCTC 14435BP, Accession Date 2021.01.06), Lactobacillus plantarum MG4553 (Accession No.: KCTC 14097BP, Accession Date 2020.01.07), Lactobacillus Plantarum MG4555 (Accession Number: KCTC 14437BP) , Accession Date 2021.01.06) or Lactobacillus rhamnosus MG4502 (Accession No.: KCTC 14095BP, Accession Date 2020.01.07).

Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555 or Lactobacillus rhamnosus MG4502 of the present invention can all exhibit excellent lipid accumulation inhibitory ability, through which It may exhibit anti-obesity activity.

In addition, the Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555, and Lactobacillus rhamnosus MG4502 strains of the present invention exhibit high α-glucosidase inhibitory activity.

Two digestive enzymes used when carbohydrates are digested into glucose are α-amylase and α-glucosidase. This strain inhibits α-glucosidase activity by inhibiting the action of α-glucosidase. It slows the rate at which polysaccharides are broken down into glucose in the intestine, helping the sugars to be absorbed into the body more slowly. This activity allows the strain to have the effect of preventing or improving not only obesity, but also various obesity-related diseases and metabolic syndrome.

In addition, the strain of the present invention exhibits a high level of free radical scavenging activity, and has high antioxidant activity by inhibiting active oxygen production, thereby exhibiting various physiological activities based thereon.

Accordingly, the strain of the present invention may have at least one activity selected from the group consisting of lipid accumulation inhibitory activity, α-glucosidase inhibitory activity and antioxidant activity.

In addition, Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555 or Lactobacillus rhamnosus MG4502 of the present invention are all suitable for probiotics, acid resistance and autologous bile tolerance It may be characterized as having a cohesive ability.

In one embodiment of the present invention, the Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555 or Lactobacillus rhamnosus MG4502 strains are pH 2 to 4 under strong acid conditions. It was confirmed that the high survival rate was maintained. In addition, in one embodiment of the present invention, the Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555, or Lactobacillus rhamnosus MG4502 are pH 7 and pH 8 It was confirmed that the high survival rate was maintained even in an environment of bile salts containing pancreatin.

In addition, the Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555, or Lactobacillus rhamnosus MG4502 strains of the present invention have excellent autoaggregation ability. It can prevent the removal of probiotics by intestinal spasm and effectively form colonies in the epithelial cells of the digestive tract in the intestine.

The strain of the present invention may have sensitivity or resistance to various antibiotics, and may be appropriately prescribed or ingested according to its unique characteristics.

More specifically, Lactobacillus acidophilus MG4558 of the present invention has sensitivity to one or more antibiotics selected from the group consisting of ampicillin, streptomycin, tetracycline, erythromycin, vancomycin and clindamycin, gentamicin, kanamycin and chloramphenicol It may be one having resistance to one or more antibiotics selected from the group consisting of.

In addition, the Lactobacillus paracasei MG4592 strain of the present invention has sensitivity to at least one antibiotic selected from the group consisting of ampicillin, gentamicin, streptomycin, tetracycline, erythromycin and clindamycin, and is selected from the group consisting of kanamycin and chloramphenicol. It may be resistant to one or more antibiotics.

In addition, the Lactobacillus plantarum MG4553 strain of the present invention has sensitivity to one or more antibiotics selected from the group consisting of ampicillin, gentamicin, kanamycin, erythromycin and clindamycin, and at least one selected from the group consisting of tetracycline and chloramphenicol. It may be resistant to antibiotics.

In addition, the Lactobacillus plantarum MG4555 strain of the present invention has sensitivity to one or more antibiotics selected from the group consisting of ampicillin, gentamicin, kanamycin, erythromycin, chloramphenicol and clindamycin, and may have resistance to tetracycline. .

In addition, the Lactobacillus rhamnosus MG4502 strain of the present invention may have sensitivity to one or more antibiotics selected from the group consisting of ampicillin, gentamicin, kanamycin, streptomycin, tetracycline, erythromycin, chloramphenicol and clindamycin.

The present invention also provides Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555, or Lactobacillus rhamnosus MG4502 strain, a culture medium thereof, or cell-free thereof It relates to a composition comprising the extract.

The composition includes a food composition for preventing or improving obesity or obesity-related diseases, a health functional food composition, a food additive composition, a quasi-drug composition, a feed composition, or a pharmaceutical composition for preventing or treating obesity or obesity-related diseases.

In the present invention, the culture medium means cultured by inoculating the strain in a liquid medium, and the cell-free extract means a supernatant from which the strain is removed from the liquid culture medium, which can be used interchangeably with "culture filtrate" have.

As used herein, the term "prevention" may refer to any action that inhibits or delays the onset of obesity-related diseases by administering the composition for preventing or treating obesity-related diseases according to the present invention to an individual.

As used herein, the term "treatment" may refer to any action for improving or benefiting the symptoms of obesity-related disease by administering the composition according to the present invention to an individual suspected of having an obesity-related disease.

As used herein, the term “improvement” may refer to any action that at least reduces a parameter related to a condition to be treated, for example, the degree of a symptom.

As used herein, the term "individual" may refer to any animal, including humans, that has or is likely to develop an obesity-related disease.

When the composition of the present invention is a food or a health functional food composition, the type of the food is not particularly limited, and may include any food in a conventional sense. Non-limiting examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea , drinks, alcoholic beverages, and vitamin complexes. When the composition is used as a food additive, the composition may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method.

As used herein, food means a natural product or processed product containing one or more nutrients, and preferably means a state that can be eaten directly through a certain processing process, and has a conventional meaning, The food composition is intended to include all food, food additives, health functional food and beverage.

Foods to which the composition of the present invention can be added include, for example, various foods, beverages, gums, candy, tea, vitamin complexes, functional foods, and the like. In addition, in the present invention, foods include special nutritional foods (eg, formula milk, infant food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (eg, ramen, noodles, etc.), health supplements, seasoned foods ( Ex, soy sauce, soybean paste, gochujang, mixed soy sauce, etc.), sauces, sweets (e.g. snacks), dairy products (e.g. fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickles, etc.), beverages (eg, fruit and vegetable beverages, soy milk, fermented beverages, ice cream, etc.), natural seasonings (eg, ramen soup, etc.), vitamin complexes, alcoholic beverages, alcoholic beverages, and other health supplements, but is not limited thereto. The food, beverage or food additive may be prepared by a conventional manufacturing method.

As used herein, the term "health functional food" refers to food manufactured and processed by methods such as extraction, concentration, purification, mixing, etc. of specific ingredients as raw materials or in food raw materials for the purpose of health supplementation, It refers to food that is designed and processed to sufficiently exert biological control functions, such as biological defense, regulation of biological rhythm, and prevention and recovery of diseases, by ingredients. say what you can

Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555, or Lactobacillus rhamnosus MG4502 strain according to the present invention, a culture solution thereof, or a cell-free extract thereof When used as a health functional food, it can be added as it is or used together with other foods or food ingredients, which can be appropriately selected and used as needed. In addition, the added Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555, or Lactobacillus rhamnosus MG4502 strain, a culture solution thereof, or a cell-free extract thereof may be appropriately determined according to the purpose of use.

Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555, or Lactobacillus rhamnosus MG4502 strain according to the present invention, a culture solution thereof, or a cell-free extract thereof Since biosafety is guaranteed and the effect of increasing the activity is proportional to the concentration, it is obvious that it can be used in an appropriate amount without being limited to a specific range.

In particular, since the strain of the present invention is a strain isolated from the body of an infant or infant, it is a strain that can be safely ingested not only by adults, but also by infants or toddlers. It can achieve antioxidant and intestinal health effects at the same time.

In addition, there is no particular limitation on the type of health functional food in which the strain according to the present invention can be used. For example, ramen, other noodles, beverages, tea, drinks, alcoholic beverages, various soups, meat, sausages, bread, chocolate, candy, confectionery, pizza, gum, dairy products including ice cream, or vitamin complex.

In particular, Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555, or Lactobacillus rhamnosus MG4502 strain according to the present invention, a culture solution thereof, or a radish thereof Since the cell extract exhibits viability, intracellular adhesion, self-aggregation and lipid accumulation inhibitory ability, α-glucosidase inhibitory activity and antioxidant activity to gastric acid or bile acid in the digestive tract, the purpose of improvement or prevention of obesity or obesity-related diseases It can be added to a variety of food products to show a function, and according to the selection of a person skilled in the art, it can be used by mixing with other suitable auxiliary ingredients and known additives that can be normally contained in health functional foods. The known additives also include other microorganisms that can be used with the strain according to the present invention.

In addition, the present invention is Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555, or Lactobacillus rhamnosus MG4502 strain, a culture medium thereof, or a cell-free extract thereof It provides a pharmaceutical composition for the prevention or treatment of obesity or obesity-related diseases comprising a.

Since the strain of the present invention exhibits excellent lipid accumulation inhibitory ability, α-glucosidase inhibitory activity and antioxidant activity, it is possible to effectively prevent or treat lipid accumulation inhibition and obesity-related diseases, preferably various metabolic diseases.

Obesity-related diseases according to the present invention may include various diseases that can be prevented and treated by inhibition of lipid accumulation in the body, inhibition of α-glucosidase and antioxidant, preferably fatty liver, type 2 diabetes, hyperlipidemia, and cardiovascular disease. It may be at least one selected from the group consisting of diseases, arteriosclerosis, and lipid-related metabolic syndrome.

In addition, since the strain of the present invention has selective resistance and sensitivity to antibiotics, it is possible to select and administer together with antibiotics with resistance.

More specifically, the Lactobacillus acidophilus MG4558 strain may be for combined administration administered in combination with one or more antibiotics selected from the group consisting of gentamicin, kanamycin and chloramphenicol.

In addition, the Lactobacillus paracasei MG4592 strain may be for combined administration, which is administered in combination with one or more antibiotics selected from the group consisting of kanamycin and chloramphenicol.

In addition, the Lactobacillus plantarum MG4553 strain may be used in combination with one or more antibiotics selected from the group consisting of tetracycline and chloramphenicol.

In addition, the Lactobacillus plantarum MG4555 strain may be for co-administration administered in combination with tetracycline.

The pharmaceutical composition according to the present invention comprises a pharmaceutically effective amount of Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555, or Lactobacillus rhamnosus MG4502 strain. , a culture solution thereof, or a cell-free extract thereof, or may include one or more pharmaceutically acceptable carriers, excipients or diluents.

As used herein, "pharmaceutically effective amount" refers to an amount sufficient to prevent, improve, or treat obesity or obesity-related diseases. The "pharmaceutically acceptable" refers to a composition that is physiologically acceptable and does not normally cause gastrointestinal disorders, allergic reactions such as dizziness, or similar reactions when administered to humans.

In addition, the pharmaceutical composition according to the present invention can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injection solutions according to conventional methods. can Suitable formulations known in the art are preferably those disclosed in Remington's Pharmaceutical Science, recently Mack Publishing Company, Easton PA. Carriers, excipients and diluents that may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose. , microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like. When formulating the pharmaceutical composition, it is usually prepared using a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, and a surfactant. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the composition, for example, starch, calcium carbonate, sucrose, lactose. , gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral use include suspensions, internal solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin oil, glycerogelatin, and the like can be used.

The pharmaceutical composition of the present invention is an amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human as considered by a researcher, veterinarian, physician or other clinician, that is, the amount of the symptom of the disease or disorder being treated. It can be administered in a therapeutically effective amount, which is an amount that induces remission. It is apparent to those skilled in the art that the therapeutically effective dosage and frequency of administration for the pharmaceutical composition of the present invention will vary depending on the desired effect. Therefore, the optimal dosage to be administered can be easily determined by those skilled in the art, and the type of disease, the severity of the disease, the content of active ingredients and other components contained in the composition, the type of formulation, and the age, weight, and general health of the patient Condition, sex and diet, administration time, administration route and secretion rate of the composition, treatment period, can be adjusted according to various factors including drugs used at the same time. For a desirable effect, the pharmaceutical composition of the present invention may be administered in an amount of 1 to 10,000 mg/kg/day, preferably 1-200 mg/kg/day, and may be administered once a day, several times It can also be administered in divided doses.

The pharmaceutical composition of the present invention may be administered to an individual by various routes. Any mode of administration can be envisaged, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebrovascular injection.

In addition, the present invention is Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555, or Lactobacillus rhamnosus MG4502 strain, a culture medium thereof, or a cell-free extract thereof It provides a quasi-drug composition for preventing or improving obesity or obesity-related diseases, including.

The strain of the present invention may be added to the quasi-drug composition for the purpose of preventing or improving obesity-related diseases. When the strain of the present invention is used as a quasi-drug additive, the strain may be added as it is or used together with other quasi-drug components, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment).

In addition, the present invention is a treatment target for livestock other than humans, Lactobacillus acidophilus MG4558, Lactobacillus paracasei MG4592, Lactobacillus plantarum MG4553, Lactobacillus plantarum MG4555, or Lactobacillus rhamnosus MG4502 strain , It provides a feed composition for preventing or improving obesity or obesity-related diseases, comprising a culture medium thereof, or a cell-free extract thereof.

The feed composition of the present invention includes a feed additive, and the feed additive of the present invention corresponds to an auxiliary feed under the Feed Management Act.

In the present invention, the term "feed" may refer to any natural or artificial diet, one-meal, etc., or a component of the one-meal, which is suitable for or suitable for the animal to eat, ingest, and digest. The type of feed is not particularly limited, and feed commonly used in the art may be used. Non-limiting examples of the feed include plant feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, gourds or grain by-products; and animal feeds such as proteins, inorganic materials, oils and fats, minerals, oils and fats, single cell proteins, zooplankton or food. These may be used alone or in mixture of two or more.

Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes of the present invention, and the scope of the present invention is not limited to these examples.

All experiments were repeated three times, and the results were expressed as mean ± standard deviation (SD). Statistical analysis was performed using R (version 3.6.2) and the PRIMER-E software package.

Example 1. Infants in feces Identification of strain isolation

Probiotic candidates were isolated from infant fecal samples. Fecal samples were collected from infants between 2 and 15 months of age. A portion of raw meal (1g) was inoculated into 9mL of 0.85% NaCl, mixed well for 3 minutes using a Stomacher sample mixer (3M, Korea), and then Whatman No. 2 filtered through filter paper. ^{Serial dilutions (up to 10 8} ) of 1 mL aliquots of the filtered samples and incubate the samples with raffinose-bifidobacterium (RB), neomycin, paromomycin, nalidic acid and lithium chloride (NPNL) or Rogosa (Lactobacillus selective agar) was plated on agar medium. The plate was incubated at 37° C. for 24 hours, and candidate lactic acid bacterial colonies were selected and purified twice in the same medium. The purified colonies were streaked on BCP (bromo cresol purple) agar, and it was confirmed that they were lactic acid-producing bacteria based on the formation of yellow areas. The strains were maintained on MRS agar medium (Difco, USA) and stored in 20% glycerol at -80°C until use. The strain was inoculated on MRS medium or agar medium and incubated at 37° C. for 12-18 hours.

In order to obtain a cell free extract (CFE) of the strains, the microbial culture medium was sonicated, and the culture medium was dissolved. First, a culture solution was obtained by centrifugation at 3,470xg at 4°C for 5 minutes, and washed 3 times with PBS (pH 7.4) to remove the remaining MRS medium. The cell pellet was resuspended at 10 mg/mL and lysed by sonication for 3 cycles at 150 W for 30 sec, pausing for 30 sec between cycles. The lysed culture solution was filtered using a 0.2 μm syringe filter (Advantech, USA) and stored at -80°C until use.

Example 2. Evaluation of strain activity

2.1 Confirmation of lipid accumulation inhibitory activity

16S rRNA gene sequencing was performed on colonies isolated from infant feces, and 61 isolated strains were identified based on the 16S rRNA gene sequencing results. Candidate strains were classified into 10 species in 2 genera and are shown in Table 1 : Bifidobacterium animalis subsp . lactis , B. breve , Lactobacillus acidophilus, L. casei , L. fermentum, L. gasseri , L. paracasei , L. plantarum , L. rhamnosus and L. salivarius.

To select a probiotic strain expected to have an anti-obesity effect, the lipid accumulation inhibitory effect of all 61 strains using differentiated 3T3-L1 adipocytes was evaluated by measuring the Oil Red O staining intensity.

3T3-L1 cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Subcultures were performed every 2 days to maintain an appropriate number of cells, and to induce adipocyte differentiation, 3T3-L1 cells were seeded in 6-well plates with DMEM at 1 x 10 ⁵ cells/mL and for a minimum of 2 days. incubated during Then the medium was replaced with DMEM-MDI (0.5mM IB M X , 1μM D EX and 1μg / mL insulin (i nsulin) content). On days 2 and 4, the culture medium was replaced with a medium containing only insulin 1 μg/mL, and on days 0, 2 and 4, cells were treated with 0.1 mg/mL of CFE along with induction medium. Thereafter, the medium was changed every 2 days for 8 days to induce differentiation.

Total lipid accumulation in differentiated 3T3-L1 adipocytes was measured using Oil Red O staining. The medium was removed from the cultured 3T3-L1 cells, and the cells were washed twice with PBS (pH 7.4). Then, 1 mL of 3.7% formaldehyde was added to each well and incubated for 15 minutes to fix the cells. Next, formaldehyde was removed and the cells were washed 3 times with PBS. Oil Red O was mixed with distilled water in a ratio of 6: 4 and filtered through a 0.2 μm filter. An aliquot of the prepared Oil Red O solution (500 μL) was added to each well, incubated at room temperature for 30 minutes, washed 3 times with PBS, and the cells were observed under a microscope. Finally, Oil Red O staining was quantified by extracting the dye with 100% isopropanol and measuring the absorbance at 540 nm using a microplate reader. 3T3-L1 cells treated with MDI formed more lipid droplets than untreated cells (control). Lipid accumulation in differentiated 3T3-L1 adipocytes was calculated using the following formula.

Lipid accumulation (%) = A _s /A _c × 100

A _s is the absorbance of MDI in the presence of sample at 540 nm, and A _c is the absorbance of MDI in the absence of sample at 540 nm.

The lipid accumulation inhibition rates of the candidate strains are shown in Table 1, and varied greatly depending on the strains.

strains Inhibition lipid accumulation ( % ) Bifidobacterium animalis subsp. lactis MG4589 -42.8 ± 1.1 Bifidobacterium breve MG4528 -31.3 ± 20.6 Lactobacillus acidophilus MG4558 - 60.4 ± 11.4 MG4559 -36.6 ± 8.9 MG4571 -8.8 ± 4.5 MG4573 45.0 ± 4.2 Lactobacillus casei MG4584 -87.3 ± 6.2 Lactobacillus fermentum MG4500 -40.1 ± 6.8 MG4510 -58.8 ± 14.8 MG4529 -52.9 ± 7.2 MG4530 -56.5 ± 1.4 MG4531 18.2 ± 16.3 MG4532 -9.8 ± 7.2 MG4533 -36.2 ± 3.2 MG4534 -43.1 ± 9.1 MG4535 -41.5 ± 0.5 MG4536 -40.3 ± 0.1 MG4538 -39.4 ± 1.6 MG4539 -41.7 ± 2.5 MG4540 -48.8 ± 1.8 MG4542 -21.7 ± 15.2 MG4543 -21.2 ± 19.7 MG4544 -16.9 ± 14.5 MG4545 -59.1 ± 3.2 Lactobacillus gasseri MG4513 12.1 ± 6.0 MG4514 20.8 ± 1.8 MG4515 31.9 ± 7.0 MG4520 -2.8 ± 3.0 MG4521 16.4 ± 11.5 MG4523 29.4 ± 11.5 MG4524 -70.3 ± 6.8 MG4503 -8.3 ± 4.1 MG4506 2.8 ± 6.1 MG4507 -4.3 ± 5.1 MG4508 -9.0 ± 4.4 MG4512 1.7 ± 2.2 MG4575 -46.1 ± 3.9 MG4582 -72.9 ± 3.1 MG4583 -53.6 ± 4.0 MG4588 -99.0 ± 6.2 MG4594 7.7 ± 13.8 Lactobacillus paracasei MG4577 32.2 ± 9.6 MG4592 -77.3 ± 3.3 Lactobacillus plantarum MG4519 -48.4 ± 11.4 MG4537 -79.6 ± 0.8 MG4553 -84.1 ± 5.3 MG4554 -92.5 ± 1.4 MG4555 -79.3 ± 4.6 MG4556 -25.5 ± 45.7 MG4557 -29.1 ± 18.4 MG4585 -93.2 ± 3.3 MG4586 -54.3 ± 10.7 MG4587 -80.0 ± 0.7 MG4591 -58.0 ± 1.0 Lactobacillus rhamnosus MG4501 -74.5 ± 7.5 MG4502 -97.3 ± 4.0 MG4511 -77.5 ± 7.8 MG4505 -85.1 ± 7.0 Lactobacillus salivarius MG4525 35.4 ± 3.7 MG4526 -44.3 ± 10.4 MG4527 -2.0 ± 12.5

Among the isolated and identified strains from infants, 25 excellent strains having a lipid accumulation inhibition ability of >50% were selected, and these strains were evaluated for fermentation product yield (>1×10 ¹¹ CFU/g). Finally, 5 strains having excellent both yield and lipid accumulation inhibition were selected, and these were deposited at the Korea Research Institute of Bioscience and Biotechnology: Lactobacillus acidophilus MG4558 (Accession No. KCTC14438BP, access date 2021.01.06), Lactobacillus para Casei MG4592 (Accession No.: KCTC 14435BP, Accession Date 2021.01.06), Lactobacillus plantarum MG4553 (Accession No.: KCTC14097BP, Accession Date 2020.01.07), Lactobacillus Plantarum MG4555 (Accession Number: KCTC 14437BP, Accession) date 2021.01.06) or Lactobacillus rhamnosus MG4502 (Accession No.: KCTC 14095BP, Accession Date 2020.01.07) (p <0.001).

2.2 Evaluation of anti-diabetic activity of strains

The effect of the selected strains having the ability to inhibit lipid accumulation on α-glucosidase activity was investigated. To a reaction mixture containing 150 µL of 0.01 M PBS (pH 7.0) and 75 µL of 0.02 M p-nitrophenyl α-D-glucopyranoside (PNPG) solution, add 25 µL of CFS and add 25 µL of CFS at 37 °C for 10 min. pre-cultured. The reaction was started by adding 50 μL of α-glucosidase (0.17 unit/mL), and the mixture was incubated at 37° C. for 10 minutes. The reaction was _{terminated by adding 1 mL of 0.1M Na 2} CO ₃ , and the amount of ρ-nitrophenol (PNP) released was measured by measuring the absorbance at 405 nm. The inhibition rate was calculated according to the following equation.

Inhibition rate (%) = [1 - (C - D)/(A - B)] × 100

A is the absorbance of α-glucosidase alone, B is the absorbance of the sample or in the absence of α-glucosidase, C is the absorbance of α-glucosidase and the sample, and D is the absorbance of the sample alone.

The results of examining the effects of the selected 7 strains on α-glucosidase activity are shown in FIG. 1 .

As shown in FIG. 1 , most of the selected strains exhibited relatively high α-glucosidase inhibitory activity, and in order of the most excellent activity, Lactobacillus plantarum MG4555 (91.6%), Lactobacillus acidophilus S. MG4558 (90.3%), Lactobacillus paracasei MG4592 (81.7%), Lactobacillus rhamnosus MG4502 (63.4%), Lactobacillus plantarum MG4553 (62.1%), Lactobacillus rhamnosus MG4505 (57.5%) and Lactobacillus rhamnosus MG4505 (57.5%). Bacillus rhamnosus MG4511 (19.8%) showed activity. Lactobacillus rhamnosus among 7 strains It was confirmed that all strains other than MG4511 (19.8%) showed excellent effects by showing lipid accumulation inhibition and α-glucosidase inhibitory activity of 50% or more. Since α-glucosidase plays a role in digesting dietary starch and decomposing oligosaccharides into glucose to rapidly increase postprandial glucose, α-glucosidase inhibitors act as oral antidiabetic agents and may be used in the treatment of type 2 diabetes mellitus (T2D). is being used Therefore, it was confirmed that the probiotic strains of the present invention exhibiting α-glucosidase inhibitory activity can be used not only for fat suppression but also as a therapeutic agent for diabetes, which is one of obesity-related diseases.

2.3 Evaluation of Antioxidant Activity of Strains

The antioxidant activity of selected strains was evaluated using DPPH and ABTS radical scavenging assays. The strain was mixed with 0.05 mM DPPH solution (1:2) and adjusted to an OD600 of 1.0. The mixture was then incubated at room temperature for 30 minutes in the dark. A control was prepared by mixing ethanol and DPPH solution. The supernatant was obtained by centrifugation at 13,000 rpm for 1 minute, and then absorbance was measured at 517 nm. Each sample was measured in triplicate. The results were compared with ascorbic acid (100 μg/mL), a representative antioxidant, and the scavenging activity was calculated using the following equation.

Scavenging effect (%) = (A _c - A _s )/A _c × 100

A _s is the absorbance of the target sample at 517nm, A _c is the absorption of the control group

To confirm the ABTS scavenging activity, a radical cation was prepared by mixing 7 mM ABTS, 2.45 mM and potassium sulfate (1:1, v/v), and incubated at room temperature in the dark for 24 hours. Thereafter, the strain was mixed (1:2) with the ABTS solution _{, adjusted to an OD 600} of 1.0, and incubated at room temperature in the dark for 10 minutes. The reaction mixture was centrifuged at 13,000 rpm for 1 minute and the absorbance of the supernatant was measured at 734 nm. Each assay was performed in triplicate. The results were compared with ascorbic acid (100 μg/mL), a representative antioxidant, and the activity was calculated using the following equation.

Scavenging rate (%) = (A _c - A _s )/A _c × 100

A _s is the absorbance of the target sample at 734nm, A _c is the absorption of the control group

The results of confirming the antioxidant capacity of each strain measured through DPPH free radical scavenging activity and ABTS free radical scavenging activity are shown in FIG. 2 .

As shown in FIG. 2 , the DPPH free radical scavenging activity of the 7 strains ranged from 21.6% to 27.5%, and the ABTS radical scavenging activity ranged from 40.9% to 44.9%, indicating overall similar O ₂ radical scavenging activity. All strains showed a higher level of radical scavenging ability in the ABTS assay than in the DPPH assay, and it was confirmed that they had antioxidant activity.

2.4. Correlation analysis of anti-obesity, anti-diabetic, and antioxidant activity

The correlation between DPPH and ABTS scavenging activity, α-glucosidase inhibition and lipid accumulation inhibition in the strain of the present invention was evaluated by multiple means comparison and Pearson correlation analysis, and the results are shown in Table 2.

Significant correlation results in Table 2 are indicated by bold and asterisk marks. As shown in Table 2, ABTS scavenging activity (p < 0.01) and α-glucosidase inhibition (p < 0.05) were significantly correlated with lipid accumulation inhibition. However, there was no statistically significant correlation between DPPH scavenging activity and other characteristics (p>0.05).

These results show that there is a significant correlation between the lipid accumulation inhibitory activity of the strain of the present invention and the α-glucosidase inhibitory activity, indicating that the strain of the present invention can simultaneously improve the status of obesity and type 2 diabetes. It is the result.

Example 3. Morphological Analysis

Morphological analysis of the selected strain having lipid accumulation inhibition, antidiabetic and antioxidant activity was performed by electron micrograph using FE-SEM (Hitachi, S-4300SE, Japan), and the results are shown in FIG. 3 .

As shown in FIG. 3 , all strains were rod-shaped bacilli, and most strains, particularly Lactobacillus rhamnosus MG4502, MG4505 and MG4511, were cells connected by exopolysaccharide (EPS) strands. confirmed that there is.

Example 4. of the selected strain acid resistance and biliary tolerance Confirm

In order to be utilized as probiotics, resistance to acid and bile leaves is important, so it was exposed to gastric juice environment (pH 3 and 4) and intestinal environment (pH 7 and 8), and the survival rate in these environments was confirmed. Specifically, after culturing the selected strain for 18 hours, the cells harvested by centrifugation (4° C., 5 minutes, 3,750 x g) were washed twice with PBS (pH 7.4). The washed strain 10 ⁸ CFU/mL was resuspended in a simulated gastric solution containing simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) and incubated at 37° C. for 3 hours. SGF was prepared using MRS culture medium containing 3 g/L of pepsin (adjusted to pH 3 and 4 with 1N HCl), and SIF was prepared using pancreatin (1 g/L) in sterile PBS (1N NaOH). and adjusted to pH 7 and 8) and prepared by mixing. The resistance of the strain was expressed as CFU/mL by counting viable cells on MRS agar plates, and the results are shown in Table 3.

strains
log CFU/mL simulated gastric fluid ^{One )} Simulated intestinal fluid ^{2 )} pH 3 pH 4 pH 7 pH 8 L. acidophilus MG4558 6.3 ± 0.1 5.5 ± 0.1 8.3 ± 0.03 8.3 ± 0.03 L. paracasei MG4592 7.9 ± 0.01 8.0 ± 0.1 7.9 ± 0.01 8.0 ± 0.03 L. plantarum MG4553 7.8 ± 0.002 7.8 ± 0.01 7.8 ± 0.02 7.8 ± 0.03 L. plantarum MG4555 7.7 ± 0.02 7.8 ± 0.01 7.8 ± 0.02 7.8 ± 0.03 L. rhamnosus MG4502 8.6 ± 0.03 8.6 ± 0.1 8.6 ± 0.1 8.5 ± 0.03 L. rhamnosus MG4511 8.6 ± 0.01 8.6 ± 0.03 8.6 ± 0.1 8.6 ± 0.1 L. rhamnosus MG4505 8.5 ± 0.1 8.6 ± 0.1 8.6 ± 0.01 8.6 ± 0.02

As shown in Table 3, all strains survived in gastric juice and bile salt conditions, which are strongly acidic and strongly basic environments, and the cell viability was 5.5 to 8.6 log CFU/mL in gastric juice conditions and 7.8 to 8.6 log CFU/mL in intestinal conditions. range was confirmed. This is a result showing that the strains of the present invention have high resistance to low pH and bile salts, which are important factors of probiotics.

Example 5. Confirmation of self-aggregation and adhesion ability of selected strains

If the self-aggregation ability of the strain is good, it is useful as a probiotic because it can prevent the removal of probiotics due to intestinal spasm and effectively form colonies in the epithelial cells of the digestive tract in the intestine. In order to confirm the self-aggregation ability of the selected lactic acid strains, they were grown in MRS medium at 37 ° C. for 18 hours, centrifuged at 3,750 x g for 5 minutes to harvest the cells, washed 3 times with PBS (pH 7.0), and then in PBS. It was resuspended to OD600 1.0. The cell suspension (4 mL) was stirred and mixed for 10 seconds and incubated at room temperature for 5 hours. The absorbance of 0.1 mL aliquots of the suspension was then measured at 600 nm with an EPOCH 2 Microplate reader (BioTek, USA). The self-cohesive capacity (%) was calculated using the following equation.

Self-cohesive capacity (%) = (1 - (A ₅ /A ₀ )) × 100

A ₅ is the absorbance at 5 hours of incubation, and A ₀ is the absorbance at time 0 immediately after starting.

Table 4 shows the results of self-aggregation and evaluation.

strains Auto-aggregation ( % ) L. acidophilus MG4558 94.3 ± 0.6 L. paracasei MG4592 40.2 ± 3.9 L. plantarum MG4553 62.0 ± 1.2 L. plantarum MG4555 56.3 ± 2.2 L. rhamnosus MG4502 34.0 ± 3.6 L. rhamnosus MG4511 41.1 ± 4.2 L. rhamnosus MG4505 49.7 ± 3.1

As shown in Table 4, Lactobacillus acidophilus MG4558 showed the strongest aggregation ability (94.3%), and they immediately aggregated to form precipitates and clear solutions. The other strains showed a self-aggregation capacity of 40-62%, and the suspension formed a precipitate but remained partially turbid.

Example 5. Enzyme Activity and Carbohydrates availability Confirm

Enzyme activity was confirmed to confirm safety as a probiotic. To measure the enzyme activity and carbohydrate availability of the selected strain, the bacteria were incubated on MRS agar plates at 37° C. for 18 hours. API ZYM and API 50 CHL kits were used according to the manufacturer's instructions (BioMerieux, France) and colonies were selected for analysis. Enzyme activity was evaluated on a scale of 0 (no activity) to 5 (product release amount of 40 nM or more) at 10 nM intervals based on the API ZYM color response chart, and the results are shown in Table 5.

All seven strains showed overall high leucine arylamidase activity, but β-glucuronidase, α-mannosidase, or trypsin No activity was shown. Among the strains, Lactobacillus rhamnosus MG4502, MG4511 and MG4505 showed relatively higher alkaline phosphatase, lipase (C14), α-chymotrypsin, α-galactosidase and α-fucosidase activities than other strains. .

For carbohydrate metabolism evaluation of each strain, the utilization rate was evaluated using the API 50 CHL system, and the results are shown in Table 6.

All strains were D-galactose, D-glucose, D-fructose, D-mannose, N-acetyl-glucosamine, amygdalin, arbutin, esculin, salicin, D-cellobiose (D- cellobiose), D-trehalose, D-melezitose and gentiobiose were fermented. However, all strains are glycerol, erythritol, L-xylose, D-adonitol, methyl-β D-xylopyranoside (methyl-βD-xylopyranoside) , methyl-α D-glucoside, inulin, D-raffinose, starch, glycogen, xylitol, D-xylose, D-fucose, D-arabitol, 2-keto-gluconate and 5-keto-gluconate failed to ferment.

Example 6. Confirmation of antibiotic resistance of the strain

Antibiotic resistance of the selected strains was evaluated by determining the minimum inhibitory concentration (MIC) of nine antibiotics and the epidemiologic cutoff value suggested by the EFSA guidelines. The strains were grown in MRS medium at 37 °C for 18 h, then harvested by centrifugation at 3,750 x g for 5 min, washed 3 times with PBS (pH 7.0), and then resuspended in PBS with 0.5 McFarland standard. The cell suspension was inoculated on Brain Heart Infusion agar (BHI; Difco, USA) with a cotton swab and the plate was dried for 10-15 min. MIC test strips (Liofilchem, Italy) were then placed on the agar surface according to the manufacturer's recommendations. Table 7 shows the results of confirming the antibiotic resistance of each strain after incubating the plate at 37° C. for 20 hours.

As shown in Table 7, most strains were most susceptible to ampicillin, gentamicin, streptomycin, erythromycin, and clindamycin, and only Lactobacillus acidophilus MG4558 was resistant to gentamicin, kanamycin and chloramphenicol. there was Resistance to antibiotics allows probiotic strains to survive in the gastrointestinal tract even during antibiotic treatment, so it can be utilized during antibiotic treatment.

Example 7. Hemolytic evaluation of selected strains

An experiment was performed to evaluate hemolysis, a major virulence factor of pathogenic bacteria. First, the strain was streaked in Tryptic Soy Agar (TSA) medium containing 5% sheep blood and incubated at 37° C. for 48 hours. After incubation, the formation of clear regions (β-hemolysis), green regions (α-hemolysis) or no regions (γ-hemolysis, non-hemolysis) around colonies was observed on the plate. As a result, all tested selection strains showed γ-hemolysis, ie, non-hemolytic properties, at 48 hours of incubation on blood agar plates, confirming that they were all safe strains.

Korea Institute of Bioscience and Biotechnology KCTC14438BP 20210106 Korea Institute of Bioscience and Biotechnology KCTC14437BP 20210106 Korea Institute of Bioscience and Biotechnology KCTC14435BP 20210106 Korea Institute of Bioscience and Biotechnology KCTC14097BP 202000107 Korea Institute of Bioscience and Biotechnology KCTC14095BP 202000107

Claims (12)

Lactobacillus paracasei MG4592 strain (Accession No.: KCTC 14435BP) strain, including its culture medium or a cell-free extract thereof,
The strain has acid resistance, bile resistance and self-aggregation ability,
It has sensitivity to one or more antibiotics selected from the group consisting of ampicillin, gentamicin, streptomycin, tetracycline, erythromycin and clindamycin, and is resistant to one or more antibiotics selected from the group consisting of kanamycin and chloramphenicol, A food composition for preventing or improving obesity.
The food composition for preventing or improving obesity according to claim 1, wherein the strain is isolated from the feces of infants or infants.
The food composition for preventing or improving obesity according to claim 1, wherein the strain has lipid accumulation inhibitory ability, α-glucosidase inhibitory activity and antioxidant activity.
delete delete delete Lactobacillus paracasei MG4592 strain (Accession No.: KCTC 14435BP) strain, including its culture medium or a cell-free extract thereof,
The strain has acid resistance, bile resistance and self-aggregation ability,
It has sensitivity to one or more antibiotics selected from the group consisting of ampicillin, gentamicin, streptomycin, tetracycline, erythromycin and clindamycin, and is resistant to one or more antibiotics selected from the group consisting of kanamycin and chloramphenicol,
A health functional food composition for preventing or improving obesity.
Lactobacillus paracasei MG4592 strain (Accession No.: KCTC 14435BP) strain, including its culture medium or a cell-free extract thereof,
The strain has acid resistance, bile resistance and self-aggregation ability,
It has sensitivity to one or more antibiotics selected from the group consisting of ampicillin, gentamicin, streptomycin, tetracycline, erythromycin and clindamycin, and is resistant to one or more antibiotics selected from the group consisting of kanamycin and chloramphenicol,
A pharmaceutical composition for preventing or treating obesity.
delete The pharmaceutical composition for preventing or treating obesity according to claim 8, wherein the composition is for administration in combination with one or more antibiotics selected from the group consisting of kanamycin and chloramphenicol.
Lactobacillus paracasei MG4592 strain (Accession No.: KCTC 14435BP) strain, including its culture medium or a cell-free extract thereof,
The strain has acid resistance, bile resistance and self-aggregation ability,
It has sensitivity to one or more antibiotics selected from the group consisting of ampicillin, gentamicin, streptomycin, tetracycline, erythromycin and clindamycin, and is resistant to one or more antibiotics selected from the group consisting of kanamycin and chloramphenicol, A quasi-drug composition for preventing or improving obesity.
Lactobacillus paracasei MG4592 strain (Accession No.: KCTC 14435BP) strain, including its culture medium or a cell-free extract thereof,
The strain has acid resistance, bile resistance and self-aggregation ability,
It has sensitivity to one or more antibiotics selected from the group consisting of ampicillin, gentamicin, streptomycin, tetracycline, erythromycin and clindamycin, and is resistant to one or more antibiotics selected from the group consisting of kanamycin and chloramphenicol, A feed composition for preventing or improving obesity.

Images